Tags

Type your tag names separated by a space and hit enter

The effects of rosiglitazone and metformin on the plasma concentrations of resistin in patients with type 2 diabetes mellitus.
Metabolism. 2005 Mar; 54(3):314-20.M

Abstract

Resistin is a protein secreted from adipose tissue that is thought to play a role in insulin sensitivity. We examined the effects of rosiglitazone and metformin on the plasma resistin levels in individuals with type 2 diabetes mellitus. Patients with type 2 diabetes mellitus who showed poor glycemic control with glimepiride (4 mg/d) were randomized to rosiglitazone (4 mg/d) and metformin (500 mg bid) treatment groups. All subjects continued glimepiride treatment as well. The plasma concentrations of resistin were measured at baseline and at 6 months of treatment for both groups. The anthropometric parameters, fasting plasma glucose, HbA1c, total cholesterol, triglyceride, high-density lipoprotein cholesterol, free fatty acids, and adiponectin concentrations were also measured. After 6 months of treatment, the reduction in plasma glucose levels was similar between the 2 groups. There were no significant changes in the lipid profiles of either group during the study period. The plasma resistin levels decreased in the rosiglitazone group (2.49 +/- 1.93 vs 1.95 +/- 1.59 ng/ml; P < .05) but increased in the metformin group (2.61 +/- 1.69 vs 5.13 +/- 2.81 ng/ml; P < .05). The plasma adiponectin concentrations were increased in the rosiglitazone group (2.91 +/- 1.46 vs 4.23 +/- 1.77 microg/ml; P < .05) but were unchanged in the metformin group. In summary, rosiglitazone treatment decreased the plasma resistin levels whereas metformin treatment increased them in patients with type 2 diabetes mellitus showing poor glycemic control with sulfonylurea therapy. These results suggest that the observed changes in plasma resistin levels are not the consequences of improved insulin resistance, nor are they consequences of glycemic control. Considering the potential role of resistin in insulin resistance, decrease in resistin levels may contribute to improving insulin action with rosiglitazone treatment.

Authors+Show Affiliations

Department of Internal Medicine, Seoul National University College of Medicine, Seoul 110-744, Korea.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

15736108

Citation

Jung, Hye Seung, et al. "The Effects of Rosiglitazone and Metformin On the Plasma Concentrations of Resistin in Patients With Type 2 Diabetes Mellitus." Metabolism: Clinical and Experimental, vol. 54, no. 3, 2005, pp. 314-20.
Jung HS, Youn BS, Cho YM, et al. The effects of rosiglitazone and metformin on the plasma concentrations of resistin in patients with type 2 diabetes mellitus. Metabolism. 2005;54(3):314-20.
Jung, H. S., Youn, B. S., Cho, Y. M., Yu, K. Y., Park, H. J., Shin, C. S., Kim, S. Y., Lee, H. K., & Park, K. S. (2005). The effects of rosiglitazone and metformin on the plasma concentrations of resistin in patients with type 2 diabetes mellitus. Metabolism: Clinical and Experimental, 54(3), 314-20.
Jung HS, et al. The Effects of Rosiglitazone and Metformin On the Plasma Concentrations of Resistin in Patients With Type 2 Diabetes Mellitus. Metabolism. 2005;54(3):314-20. PubMed PMID: 15736108.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The effects of rosiglitazone and metformin on the plasma concentrations of resistin in patients with type 2 diabetes mellitus. AU - Jung,Hye Seung, AU - Youn,Byung-Soo, AU - Cho,Young Min, AU - Yu,Kang-Yeol, AU - Park,Hong Je, AU - Shin,Chan Soo, AU - Kim,Seong Yeon, AU - Lee,Hong Kyu, AU - Park,Kyong Soo, PY - 2005/3/1/pubmed PY - 2005/5/3/medline PY - 2005/3/1/entrez SP - 314 EP - 20 JF - Metabolism: clinical and experimental JO - Metabolism VL - 54 IS - 3 N2 - Resistin is a protein secreted from adipose tissue that is thought to play a role in insulin sensitivity. We examined the effects of rosiglitazone and metformin on the plasma resistin levels in individuals with type 2 diabetes mellitus. Patients with type 2 diabetes mellitus who showed poor glycemic control with glimepiride (4 mg/d) were randomized to rosiglitazone (4 mg/d) and metformin (500 mg bid) treatment groups. All subjects continued glimepiride treatment as well. The plasma concentrations of resistin were measured at baseline and at 6 months of treatment for both groups. The anthropometric parameters, fasting plasma glucose, HbA1c, total cholesterol, triglyceride, high-density lipoprotein cholesterol, free fatty acids, and adiponectin concentrations were also measured. After 6 months of treatment, the reduction in plasma glucose levels was similar between the 2 groups. There were no significant changes in the lipid profiles of either group during the study period. The plasma resistin levels decreased in the rosiglitazone group (2.49 +/- 1.93 vs 1.95 +/- 1.59 ng/ml; P < .05) but increased in the metformin group (2.61 +/- 1.69 vs 5.13 +/- 2.81 ng/ml; P < .05). The plasma adiponectin concentrations were increased in the rosiglitazone group (2.91 +/- 1.46 vs 4.23 +/- 1.77 microg/ml; P < .05) but were unchanged in the metformin group. In summary, rosiglitazone treatment decreased the plasma resistin levels whereas metformin treatment increased them in patients with type 2 diabetes mellitus showing poor glycemic control with sulfonylurea therapy. These results suggest that the observed changes in plasma resistin levels are not the consequences of improved insulin resistance, nor are they consequences of glycemic control. Considering the potential role of resistin in insulin resistance, decrease in resistin levels may contribute to improving insulin action with rosiglitazone treatment. SN - 0026-0495 UR - https://www.unboundmedicine.com/medline/citation/15736108/The_effects_of_rosiglitazone_and_metformin_on_the_plasma_concentrations_of_resistin_in_patients_with_type_2_diabetes_mellitus_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S002604950400366X DB - PRIME DP - Unbound Medicine ER -